April 24 -- Viamet Pharmaceuticals, Inc. today announced that data related to its novel antifungal programs will be presented at the European Congress for Clinical Microbiology and Infectious Diseases Conference in Copenhagen, April 25 - 28, 2015.
Clinical and preclinical data will be presented for VT-1161, an oral agent currently in Phase 2b studies for the treatment of onychomycosis and recurrent vulvovaginal candidiasis:
* Poster [PO228] titled "Efficacy and Safety of Oral VT-1161, a Novel Inhibitor of Fungal CYP51, in a Randomized Phase 2a Study in Patients with Acute Vulvovaginal Candidiasis," by Brand et al.
* Poster [PO1274] titled "High In Vitro Potency of the Clinical Investigational Agent VT-1161 Against Clinical Isolates of Candida Spp.," by Long et al.
* Oral poster [EPO14] titled "VT-1161 Protects Immunosuppressed Mice from Rhizopus Oryzae Infection," by Gebremarian et al.
In addition, preclinical data will be presented for VT-1129, an oral agent currently undergoing IND-enabling studies, that the Company intends to develop for the treatment of cryptococcal meningitis and other life-threatening fungal infections:
* Poster [PO232] titled "The Novel Fungal CYP51 Inhibitor VT-1129 Demonstrates Potent In Vivo Activity Against Cryptococcal Meningitis with a Loading/Maintenance Dosing Regimen," by Wiederhold et al.
Robert Schotzinger, MD, PhD, CEO of Viamet commented, "We are pleased to present these exciting data on our broad pipeline of novel antifungal agents, including VT-1161 and VT-1129. These compounds, and others in our pipeline, are highly potent and were specifically designed to avoid the safety issues that limit currently marketed antifungal agents. We believe that Viamet has the broadest and most robust portfolio of novel antifungal agents in the industry today."
The presentations will be available on the Company's website following presentation at the conference.